Disagregin
Latest Information Update: 04 Nov 1997
At a glance
- Originator Merck & Co
- Class Antithrombotics; Salivary proteins and peptides
- Mechanism of Action Fibrinogen receptor antagonists; GPIIb-IIIa antagonists; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 04 Nov 1997 No-Development-Reported for Thrombosis in USA (Unknown route)
- 28 Nov 1995 New profile
- 28 Nov 1995 Preclinical development for Thrombosis in USA (Unknown route)